Alkermes Plc (NASDAQ:ALKS)
| 19.05 Delayed Data As of Feb 26 |  -0.39 / -2.01%Today’s Change | 11.98 Today|||52-Week Range 23.92 | -4.51% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.0B |
Company Description
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
Contact Information
Alkermes Plc Connaught House Dublin Dublin 4 |
Employees
Shareholders
| Mutual fund holders | 55.16% |
| Other institutional | 47.16% |
| Individual stakeholders | 1.45% |
Top Executives
| Richard F. Pops | Chairman & Chief Executive Officer |
| Blair C. Jackson | Chief Operating Officer & Executive Vice President |
| Iain Michael Brown | Senior VP, Chief Financial & Accounting Officer |
| Kanchan Relwani | Senior Vice President-Medical Affairs |
| Craig C. Hopkinson | Chief Medical Officer & EVP-Research & Development |
